LONDON, ENGLAND — March 21, 2002 — Results published today in Clinical Therapeutics have shown that patients with type 2 diabetes who were prescribed Actos® (pioglitazone) achieved significantly greater improvement across the whole lipid profile compared to patients treated with rosiglitazone.
The EVIDENT study (Effects of Pioglitazone and Rosiglitazone on Blood Lipids and Glycemic Control of Patients with Type 2 Diabetes) was a national US, multicentre, retrospective random review of 1,115 selected medical records. The results showed that while each drug achieved similar glycaemic control there were significant differences between the two, which may have important implications for cardiovascular risk among patients with type 2 diabetes. In patients prescribed Actos there was an increase in HDL (high-density lipoprotein) cholesterol concentrations and a reduction in total cholesterol, LDL (low density lipoprotein) cholesterol, and triglycerides concentrations.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!